How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/primary-prevention-of-coronary-heart-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Primary Prevention of Coronary Heart Disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Primary Prevention of Coronary Heart Disease (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Primary Prevention of Coronary Heart Disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Crestor	rosuvastatin	AstraZeneca	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lipitor	Atorvastatin Calcium	Pfizer	atorvastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1996-01-01
Norvasc	amlodipine	Pfizer Inc.	Calcium channel blocker (dihydropyridine)	Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6	1992-07-31
Mevacor	LOVASTATIN	Merck & Co.	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1987-01-01
Lopid	GEMFIBROZIL	Pfizer	Peroxisome Proliferator Receptor alpha Agonist [EPC]	Transthyretin	1981-01-01
Amlodipin	Amlodipin	Boehringer Ingelheim		Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Primary Prevention of Coronary Heart Disease
Pfizer Inc. · 2 drugs in Primary Prevention of Coronary Heart Disease
AstraZeneca · 1 drug in Primary Prevention of Coronary Heart Disease
Boehringer Ingelheim · 1 drug in Primary Prevention of Coronary Heart Disease
Merck & Co. · 1 drug in Primary Prevention of Coronary Heart Disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Primary Prevention of Coronary Heart Disease:

Cite this brief

Drug Landscape (2026). Primary Prevention of Coronary Heart Disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/primary-prevention-of-coronary-heart-disease. Accessed 2026-06-10.

Primary Prevention of Coronary Heart Disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing